AU Patent

AU2017393082B2 — Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment

Assigned to Agenebio Inc · Expires 2022-04-21 · 4y expired

What this patent protects

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS)…

USPTO Abstract

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5- containing GABA

Drugs covered by this patent

Patent Metadata

Patent number
AU2017393082B2
Jurisdiction
AU
Classification
—
Expires
2022-04-21
Drug substance claim
No
Drug product claim
No
Assignee
Agenebio Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.